TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00001723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
Study: NCT03916276

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy (CT)
Description: The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts; recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation (MM)
Description: Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activation Skills (AS)
Description: Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
Study: NCT02788357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
Study: NCT02511483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric assessment
Description: Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: COMT-haplotypes
Description: Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: COMT-haplotypes
Description: Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
Study: NCT03354546

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty index
Description: A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty index
Description: A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
Study: NCT03014310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
Study: NCT03647410

Intervention type: DEVICE
Intervention: lumbopelvic fixation
Description: Sacral fractures fixed with lumbopelvic fixation or novel adjustable plate were divided into two groups. Surgical time, intraoperative blood loss, frequency of intraoperative fluoroscopy, reduction quality, related complications, and functional outcome were reviewed.
Study: NCT04570605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: parasacral transcutaneous electrical nerve stimulation (PTENS)
Description: electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Urotherapy
Description: standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Urotherapy
Description: standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
Study: NCT00926419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Vaccine
Description: Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Vaccine
Description: Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A virus vaccine, inactivated, Single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A virus vaccine, inactivated, Single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A Vaccine
Description: Hepatitis A virus vaccine, inactivated, Single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A Vaccine
Description: Hepatitis A virus vaccine, inactivated, Single dose
Study: NCT02853812

Intervention type: OTHER
Group type: OTHER
Intervention: Functional brain MRI
Description: Sound evoked functional MRI assessment on patients with single sided tinnitus
Study: NCT02370485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2801653
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2801653
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2801653
Description: Administered orally
Study: NCT04466098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Thawed product containing MSC(300x10\^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin \[total volume 60 mL\]

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextran 40 + 5% human serum albumin \[total volume 60 mL\]
Study: NCT00709527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacincaptad Pegol
Description: intravitreal injection
Study: NCT04288128

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Each participant will undergo scanning at 3 visits (M0, M6 and M12)

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Each participant will undergo scanning at 3 visits (M0, M6 and M12)
Study: NCT04209543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: Estetrol oral tablet: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: Estetrol oral tablet: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: Estetrol oral tablet: administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone oral tablet: administered orally once daily
Study: NCT03952559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Administered as standard-of-care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Administered as standard-of-care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Administered as standard-of-care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Administered as standard-of-care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroid
Description: Administered as standard-of-care
Study: NCT01730664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem
Description: single dose of 2000mg ertapenem IV
Study: NCT04067297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipid management toolbox
Description: The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of \~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
Study: NCT01465217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text message medication reminders
Description: daily medication reminders for one month
Study: NCT03677739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information focusing on skin cancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information on healthy lifestyle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04000971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Stroke Practice Unit
Description: Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, and increase understanding and build positive behavior change for patients and caregivers. Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
Study: NCT00923598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% and 0.4% perineural ropivicaine
Description: Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% and 0.4% perineural ropivicaine
Description: Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
Study: NCT00797030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine and sodium carboximethycellulose
Description: Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
Study: NCT04000971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive or Primary Stroke Center
Description: Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
Study: NCT03952598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP 13C Pyruvate
Description: Contrast agent used with magnetic resonance spectroscopic imaging (MRSI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI scanner
Description: Research proton MRS (1H-MRS) followed by DW-MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI scanner
Description: Research proton MRS (1H-MRS) followed by DW-MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI scanner
Description: Research proton MRS (1H-MRS) followed by DW-MRI
Study: NCT03657342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A
Description: This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.
Study: NCT03972202

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-motor behavioral testing
Description: Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-motor behavioral testing
Description: Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-motor behavioral testing
Description: Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
Study: NCT03656848

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: QFR
Description: QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Angiography
Description: Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
Study: NCT00700544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy treatment (see arm) + norethandrolone
Description: oral form~Dosage:~10 mg in patients with a weight \< 60 kgs 20 mg in patients with a weight \> 60 kgs frequency: every day Duration: 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy treatment (see arms)
Description: Induction chemotherapy + maintenance chemotherapy
Study: NCT03103698

Intervention type: DEVICE
Group type: OTHER
Intervention: To demonstrate the monitoring of perioperative analgesia
Description: To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard preoperative evaluation of analgesia
Description: To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
Study: NCT02740062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIBS system for evaluation and non invasive current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NIBS system for evaluation and non invasive current stimulation
Study: NCT04142424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
Study: NCT00797030

Intervention type: DRUG
Group type: OTHER
Intervention: sodium carboximethycellulose
Description: Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months